Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline


Ferring Pharmaceuticals begins Phase 2b/3 trial of selepressin for treatment of septic shock.

SAINT PREX, Switzerland, 17 August 2015 – Ferring Pharmaceuticals announced initiation of patient enrollment in a phase 2b/3 clinical trial of selepressin for the treatment of septic shock, a life-threatening complication of infection affecting millions of people worldwide annually. The trial, SEPSIS-ACT, will be conducted at 50-60 sites in Europe and the United States and will enroll 1800 patients).

Click here to read more

See more Newsroom


Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692